Koninklijke Philips N.V. operates as a health technology company in North America, Greater China, and internationally. It operates through Diagnosis & Treatment, Connected Care, and Personal Health segments. It provides magnetic resonance imaging, computed tomography, advanced molecular imaging, diagnostic X-ray, and imaging components as well as integrated clinical solutions; integrated interventional systems, including interventional diagnostic and therapeutic devices; imaging products focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; proprietary software to enable diagnostics and intervention; and enterprise diagnostic informatics products and services. The company also offers monitoring and analytics solutions; sleep and respiratory care solutions; emergency care and resuscitation, and patient management solutions; data, analytics, and actionable workflow solutions; and connected care informatics solutions. In addition, it provides power toothbrushes, brush heads, and interdental cleaning and teeth whitening products; infant feeding and digital parental solutions; male grooming and beauty products and solutions; and kitchen appliances, home care, and garment care products, as well as coffee machines. Koninklijke Philips N.V. has a partnership with openDoctor to deliver an integrated radiology patient engagement platform that leverages openDoctor's real-time online appointment scheduling services as part of its patient management solution; and a strategic collaboration with Ibex Medical Analytics Ltd. to jointly promote the digital pathology and AI solutions to hospitals, health networks, and pathology laboratories worldwide. The company was formerly known as Koninklijke Philips Electronics N.V. and changed its name to Koninklijke Philips N.V. in May 2013. Koninklijke Philips N.V. was founded in 1891 and is headquartered in Amsterdam, the Netherlands.
IPO Year:
Exchange: NYSE
Website: philips.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/25/2025 | Neutral → Outperform | Exane BNP Paribas | |
| 2/20/2025 | Neutral → Buy | UBS | |
| 10/29/2024 | Underperform → Hold | Jefferies | |
| 5/13/2024 | Mkt Perform → Outperform | Bernstein | |
| 5/7/2024 | Underperform → Neutral | Exane BNP Paribas | |
| 4/30/2024 | Sell → Neutral | UBS | |
| 4/30/2024 | Underweight → Neutral | JP Morgan | |
| 2/7/2024 | Outperform → Underperform | Exane BNP Paribas | |
| 7/12/2023 | Buy | Goldman | |
| 1/17/2023 | Neutral → Sell | UBS |
6-K - KONINKLIJKE PHILIPS NV (0000313216) (Filer)
6-K - KONINKLIJKE PHILIPS NV (0000313216) (Filer)
SD - KONINKLIJKE PHILIPS NV (0000313216) (Filer)
6-K - KONINKLIJKE PHILIPS NV (0000313216) (Filer)
6-K - KONINKLIJKE PHILIPS NV (0000313216) (Filer)
6-K - KONINKLIJKE PHILIPS NV (0000313216) (Filer)
6-K - KONINKLIJKE PHILIPS NV (0000313216) (Filer)
6-K - KONINKLIJKE PHILIPS NV (0000313216) (Filer)
20-F - KONINKLIJKE PHILIPS NV (0000313216) (Filer)
6-K/A - KONINKLIJKE PHILIPS NV (0000313216) (Filer)
June 5, 2025 Amsterdam, the Netherlands – Royal Philips (NYSE:PHG, AEX: PHIA)), today announced that the exchange ratio for the dividend for the year 2024 is 1 new common share for every 23.6353 existing common shares. This ratio was based on the volume weighted average price on Euronext Amsterdam of May 30, June 2, and 3, 2025, of EUR 20.0600 and was calculated in a manner that the gross dividend in shares will be approximately equal to EUR 0.85. As a result, Philips will issue a total number of 22,980,748 new common shares. Shareholders have been given the opportunity to make their choice between a dividend in shares or (subject to certain conditions) in cash. The aggregate cash election
May 6, 2025Q1 2025 Group performance Group sales EUR 4.1 billion, reflecting a 2% decline in comparable sales growth mainly due to China; slightly ahead of company outlook due to Personal Health growth and royalty phasingComparable order intake increased 2% despite China declineIncome from operations increased to EUR 154 millionAdjusted EBITA margin declined 80 bps to 8.6% of sales, driven by sales phasingFree cash outflow of EUR 1,091 million included EUR 1,025 million payment for Philips Respironics recall-related medical monitoring and personal injury settlements in USUpdated full year 2025 outlook for Adjusted EBITA margin and free cash flow; sales outlook remains unchanged Roy Jakobs,
March 24, 2025Amsterdam, the Netherlands – Royal Philips (NYSE:PHG, AEX: PHIA)) today announced it has convened the Annual General Meeting of Shareholders (AGM) 2025 and published the agenda with explanatory notes.As previously announced, the agenda includes: Proposal to appoint Mr Bob White (American, 1962) as a new member of the Supervisory Board, with effect from May 8, 2025.Proposals to re-appoint Ms Indra Nooyi (American, 1955) and Ms Chua Sock Koong (Singaporean, 1957) as members of the Supervisory Board, with effect from May 8, 2025.Proposal to re-appoint Mr Marnix van Ginneken (Dutch, 1973) as a member of the Philips Board of Management, with effect from May 8, 2025. The agenda fu
February 19, 2025Full Year and Q4 Group performance highlights Sales of EUR 18.0 billion in 2024, comparable sales growth 1%; EUR 5.0 billion in Q4, comparable sales growth 1%, despite double-digit decline in ChinaComparable order intake increased 1% in 2024; up 2% in Q4, despite double-digit decline in ChinaIncome from operations was EUR 529 million in 2024; EUR 199 million in Q4Adjusted EBITA margin increased 90 basis points to 11.5% of sales in 2024; up 60 basis points to 13.5% in Q4Net cash flow from operating activities was EUR 1,569 million in 2024; EUR 1,459 million in Q4Free cash flow was EUR 906 million in 2024; EUR 1,285 million in Q4Finalized Philips Respironics recall-related me
November 12, 2024 Designed specifically for use in radiation oncology, new Spectral CT 7500 RT enables personalized radiation therapy planning to deliver better care for more cancer patients Amsterdam, the Netherlands – Royal Philips (NYSE:PHG, AEX: PHIA)), a global leader in health technology, today announced a major advance in radiation oncology with 510(k) clearance from the US Food and Drug Administration (FDA) for its new detector-based spectral computed tomography (CT) radiotherapy solution. Philips Spectral CT 7500 RT marks the next step in personalized cancer care by integrating the unique tumor visualization and tissue characterization capabilities of spectral CT into cancer trea
October 28, 2024 Third-quarter highlights Group sales amounted to EUR 4.4 billion, with flat comparable sales growthIncome from operations was EUR 337 millionAdjusted EBITA margin increased by 160 basis points from 10.2% to 11.8% of salesOperating cashflow of EUR 192 million, with a free cashflow of EUR 22 millionComparable order intake decreased by 2%, due to decline in ChinaOutlook for full-year 2024 revised to reflect deteriorated demand in China: comparable sales growth within an updated range 0.5%-1.5%, Adjusted EBITA margin at around 11.5%, the upper end of current range; free cashflow at around EUR 0.9 billion, at lower end of current range Roy Jakobs, CEO of Royal Philips:
July 29, 2024 Second-quarter highlights Group sales amounted to EUR 4.5 billion, with comparable sales growth of 2%Comparable order intake increased by 9%Income from operations EUR 816 million, including EUR 538 million insurance income*)Adjusted EBITA margin increased to 11.1% of salesOperating cash inflow of EUR 89 million, with a free cash outflow of EUR 64 million Roy Jakobs, CEO of Royal Philips:"I am encouraged by our return to order intake growth this quarter, primarily driven by North America. Within a challenging macro environment we achieved strong margin improvement, supported by our productivity program, solid operational cashflow due to improved working capital m
May 15, 2024 Amsterdam, the Netherlands – Royal Philips (NYSE:PHG, AEX: PHIA))), today announced that the exchange ratio for the dividend for the year 2023 is 1 new common share for every 29.2684 existing common shares. This ratio was based on the volume weighted average price on Euronext Amsterdam of May 9, 10 and 13, 2024, of EUR 24.8481 and was calculated in a manner that the gross dividend in shares will be approximately equal to EUR 0.85. As a result, Philips will issue a total number of 30,860,582 new common shares. Distribution of the dividend with delivery of new common shares and settlement of any fractions in cash, will take place from May 16, 2024. Upon distribution, the total i
March 22, 2024 Amsterdam, the Netherlands – Royal Philips (NYSE:PHG, AEX: PHIA))), today announced it has convened the Annual General Meeting of Shareholders (AGM) 2024 and published the agenda with explanatory notes. As previously announced, the agenda includes: Proposals to re-appoint Chairman Feike Sijbesma (Dutch, 1959) and Peter Löscher (Austrian, 1957) as members of the Supervisory Board, with effect from May 7, 2024.Proposal to appoint Charlotte Hanneman (Dutch, 1978) as member of the Board of Management, fulfilling the role of Chief Financial Officer, with effect from October 1, 202
July 24, 2023 Second-quarter highlights Group sales increased to EUR 4.5 billion, with 9% comparable sales growthIncome from operations amounted to EUR 221 million, compared to EUR 11 million in Q2 2022Adjusted EBITA increased to EUR 453 million, or 10.1% of sales, compared to EUR 216 million, or 5.2% of sales, in Q2 2022Order book continued to grow year-on-year, while comparable order intake declined following a high order intake in Q2 2022Operating cash flow improved to EUR 135 million, compared to an outflow of EUR 306 million in Q2 2022Simplification of the operating model and restructuring plans on trackOutlook for full year 2023 raised to mid-single-di
In 2024, Philips Foundation initiated 22 new projects and 5 new impact investments expanding its impact and reach in innovative healthcare delivery to India and South AmericaCelebrating a decade of impact with strong progress towards the Foundation's 2030 goal to improve access to healthcare for 100 million people in underserved communities a yearThe combined impact of longstanding strategic collaborations and new innovative partnerships with healthcare ventures affirm the Foundation's approach to locally embedded innovation with flexible financing models to improve healthcare access Amsterdam, the Netherlands – Marking its tenth anniversary, Philips Foundation today released its 2024 Annua
June 5, 2025 Amsterdam, the Netherlands – Royal Philips (NYSE:PHG, AEX: PHIA)), today announced that the exchange ratio for the dividend for the year 2024 is 1 new common share for every 23.6353 existing common shares. This ratio was based on the volume weighted average price on Euronext Amsterdam of May 30, June 2, and 3, 2025, of EUR 20.0600 and was calculated in a manner that the gross dividend in shares will be approximately equal to EUR 0.85. As a result, Philips will issue a total number of 22,980,748 new common shares. Shareholders have been given the opportunity to make their choice between a dividend in shares or (subject to certain conditions) in cash. The aggregate cash election
June 4, 2025 Amsterdam, the Netherlands – Royal Philips (NYSE:PHG, AEX: PHIA)) today announced that it will repurchase up to 6 million shares to cover certain of its obligations arising from its long-term incentive plans. At the current share price, the shares represent an amount of up to approximately EUR 125 million. The repurchases will be executed through one or more individual forward transactions, to be entered into in the course of the second and third quarter of 2025, in accordance with the Market Abuse Regulation and within the limits of the authorization granted by the company's General Meeting of Shareholders on May 8, 2025. Philips expects to take delivery of the shares in 202
Collaboration designed to enhance health awareness for moms during pregnancy and improve health outcomes Aggregated analytics data and surveys from app will help provide maternal health insights Royal Philips (NYSE:PHG, AEX: PHIA)), a global leader in health technology, and March of Dimes, the nation's leading nonprofit fighting for the health of all moms and babies, today announced a collaboration aimed at improving maternal health education through the Philips Avent Pregnancy+ app. Philips will integrate essential March of Dimes content into the app to help improve health literacy and create awareness for topics such as preparing for a Neonatal Intensive Care Unit (NICU) stay, pret
May 20, 2025 Prospective, randomized, unblinded, comparative, international, multi-center clinical investigation824 patients across 6 hospitals in Spain, Czech Republic, Denmark and the USPrimary objective is to demonstrate that the new technology can reduce overall patient radiation dose without affecting coronary procedure performance. Amsterdam, the Netherlands – Royal Philips (NYSE:PHG, AEX: PHIA)), a global leader in health technology, today announced the launch of the RADIQAL (Radiation Dose and Image Quality Trial) trial. This multicenter, randomized study, sponsored by Philips will enroll 824 coronary artery disease patients across 6 hospitals in Spain, Czech Republic and the US. T
May 19, 2025 VeriSight Pro 3D ICE catheter is a pioneering innovation — a miniaturized ultrasound probe embedded at the tip of a thin, steerable catheter, navigated through the vascular system into the heart chambers to deliver high-quality 2D and 3D images in real timeCatheter offers enhanced procedural guidance without the need for general anesthesia, supporting more efficient and patient-friendly care for structural heart disease Amsterdam, the Netherlands – Royal Philips (NYSE:PHG, AEX: PHIA)), a global leader in health technology, today announced the introduction of its VeriSight Pro 3D Intracardiac Echocardiography (ICE) catheter in Europe. Building on its success in the United State
May 15, 2025 Amsterdam, the Netherlands – Royal Philips (NYSE:PHG, AEX: PHIA)), a global leader in health technology, today announced the successful pricing of its offering of EUR 500 million fixed rate notes due 2030 and EUR 500 million fixed rate notes due 2035 (the "Notes") under its European Medium Term Note (EMTN) program. The net proceeds will be used for general corporate purposes, the repayment of 2026 debt maturities, and to refinance or finance any Eligible Projects as defined in Philips' Sustainable Finance Framework. The issue price for the Notes due 2030 is 99.859% with a Coupon of 3.250%, resulting in a yield of 3.281% and the issue price for the Notes due 2035 is 99.595% wi
AI in healthcare can address some of healthcare's most pressing challenges, but trust barriers threaten progress Royal Philips (NYSE:PHG, AEX: PHIA)), a global leader in health technology, today unveiled its 2025 Future Health Index U.S. report, "Building trust in healthcare AI," spotlighting the state of healthcare and uncovering a significant trust gap between healthcare professionals (HCPs) and patients around the role of AI in healthcare. This 10th edition report, commissioned by Philips, reveals a healthcare system under mounting strain and signals that AI can help. However, gaps in trust in AI threaten to stall progress. This press release features multimedia. View the full release h
May 15, 2025AI has the power to cut care delays and manage data overload, but trust gaps among clinicians and patients threaten to slow adoption and impactAmsterdam, the Netherlands – Royal Philips (NYSE:PHG, AEX: PHIA)), a global leader in health technology, has released its 10th annual Future Health Index (FHI) report, highlighting the growing strain on global healthcare systems. The FHI 2025 Report, the largest global survey of its kind analyzing key concerns of healthcare professionals and patients, indicates AI holds promise for transforming care delivery. However, gaps in trust threaten to stall progress at a time when innovation is most needed."The need to transform healthcare deliver
Google Cloud helps streamline marketing processes, enhancing brand consistency and reducing operational costs AMSTERDAM and SUNNYVALE, Calif., May 14, 2025 /PRNewswire/ -- Google Cloud today announced a collaboration with the Philips Personal Health Business to modernize its global image library and content marketing systems. Leveraging Google Cloud's Vertex AI platform, Philips has developed a solution that enables asset management with unprecedented speed and scale, significantly reducing operational costs, enhancing brand consistency, and accelerating marketing agility. Phi
Exane BNP Paribas upgraded Philips from Neutral to Outperform
UBS upgraded Philips from Neutral to Buy
Jefferies upgraded Philips from Underperform to Hold
Bernstein upgraded Philips from Mkt Perform to Outperform
Exane BNP Paribas upgraded Philips from Underperform to Neutral
UBS upgraded Philips from Sell to Neutral
JP Morgan upgraded Philips from Underweight to Neutral
Exane BNP Paribas downgraded Philips from Outperform to Underperform
Goldman initiated coverage of Philips with a rating of Buy
UBS downgraded Philips from Neutral to Sell